The Pattern of Change in Depressive Symptoms and Inflammatory Markers After Electroconvulsive Therapy: A Systematic Review.
Journal
The journal of ECT
ISSN: 1533-4112
Titre abrégé: J ECT
Pays: United States
ID NLM: 9808943
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
24
7
2021
medline:
16
3
2022
entrez:
23
7
2021
Statut:
ppublish
Résumé
Depression is a major mental health disorder, and its pathophysiology is still largely unknown, as is the action mechanism of electroconvulsive therapy (ECT). Some evidence suggests that inflammation might play a role in depression, and several studies have attempted to demonstrate a link between ECT and cytokines. This systematic review used a qualitative analysis to assess the effect of ECT on inflammatory markers as it relates to the clinical response of depressive symptoms in major depressive disorders. The bibliographic search engines CINAHL, Embase, PsychInfo, and PubMed were used to identify articles published up to July 2020. Search terms related to depression, ECT, and inflammation were used. Descriptive statistical analyses were performed to relate changes in inflammatory markers to clinical response to ECT. Twenty-five studies were included in the analysis. No systematic increases or decreases were found in a given inflammatory marker over the ECT; however, we observed that tumor necrosis factor α and interleukin-6 (IL-6) were more often found to be decreased after ECT, whereas IL-8 and IL-10 were more often found to be increased after treatment. No trend in correlation was found between the degree of clinical improvement of depressive symptoms and the variation of any inflammatory markers, despite positive clinical response to ECT. Great heterogeneity with regard to methodology used and lack of power of the studies included in this review could explain the lack of systematic change and correlation found in this study. Future research conducted on this subject should take into account these methodological limitations to allow subsequent meta-analysis.
Identifiants
pubmed: 34294652
doi: 10.1097/YCT.0000000000000782
pii: 00124509-202112000-00015
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-297Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest or financial disclosures to report.
Références
Patten SB, Williams JVA, Lavorato DH, et al. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry . 2015;60:23–30.
Fawcett J. The morbidity and mortality of clinical depression. Int Clin Psychopharmacol . 1993;8:217–220.
Gibney S, Drexhage H. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol . 2013;8:900–920.
Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. Am J Psychiatry . 2015;172:1075–1091.
Furtado M, Katzman MA. Examining the role of neuroinflammation in major depression. Psychiatry Res . 2015;229:27–36.
Udina M, Castellví P, Moreno-España J, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry . 2012;73:1128–1138.
Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry . 2010;67:446–457.
Haapakoski R, Mathieu J, Ebmeier KP, et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun . 2015;49:206–215.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med . 2009;71:171–186.
Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl) . 2016;233:1575–1589.
Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology . 2011;36:2452–2459.
Strawbridge R, Arnone D, Danese A, et al. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol . 2015;25:1532–1543.
Bonnefoy J, Denoroy M, Guillot O, et al. Activation of normal human B cells through their antigen receptor induces membrane expression of IL-1 alpha and secretion of IL-1 beta. J Immunol . 1989;143:864–869.
Dhabhar FS, Burke HM, Epel ES, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res . 2009;43:962–969.
Song C, Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry . 2011;35:760–768.
Medda P, Perugi G, Zanello S, et al. Response to ECT in bipolar I, bipolar II and unipolar depression. J Affect Disord . 2009;118:55–59.
Guloksuz S, Rutten BP, Arts B, et al. The immune system and electroconvulsive therapy for depression. J ECT . 2014;30:132–137.
Yrondi A, Sporer M, Peran P, et al. Electroconvulsive therapy, depression, the immune system and inflammation: a systematic review. Brain Stimul . 2018;11:29–51.
Stippl A, Kirkgöze FN, Bajbouj M, et al. Differential effects of electroconvulsive therapy in the treatment of major depressive disorder. Neuropsychobiology . 2020;1–9.
Haq AU, Sitzmann AF, Goldman ML, et al. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry . 2015;76:1374–1384.
Cochrane. Cochrane Handbook for Systematic Reviews of Intervenention. Version 6.0. Cochrane; 2020. Available at www.training.cochrane.org/handbook . Accessed June 1, 2020.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol . 2009;62:e1–e34.
Kmet L, Cook L, Lee R. Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields [ERA 2004]. Available at: https://era.library.ualberta.ca/items/48b9b989-c221-4df6-9e35-af782082280e . Accessed September 7, 2018.
Kargar M, Yousefi A, Mojtahedzadeh M, et al. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly . 2014;144:w13880.
Albrecht J, Helderman JH, Schlesser MA, et al. A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiatry Res . 1985;15:185–193.
Chaturvedi S, Chadda RK, Rusia U, et al. Effect of electroconvulsive therapy on hematological parameters. Psychiatry Res . 2001;104:265–268.
Giltay EJ, Kho KH, Blansjaar BA. Serum markers of brain-cell damage and C-reactive protein are unaffected by electroconvulsive therapy. World J Biol Psychiatry . 2008;9:231–235.
Carlier A, Berkhof JG, Rozing M, et al. Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study☆. J Affect Disord . 2019;254:509–516.
Kranaster L, Hoyer C, Mindt S, et al. The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. Eur Arch Psychiatry Clin Neurosci . 2020;270:911–919.
Kranaster L, Hoyer C, Aksay SS, et al. Biomarkers for antidepressant efficacy of electroconvulsive therapy: an exploratory cerebrospinal fluid study. Neuropsychobiology . 2018;77:13–22.
Ryan KM, Glaviano A, O'Donovan SM, et al. Electroconvulsive therapy modulates plasma pigment epithelium-derived factor in depression: a proteomics study. Transl Psychiatry . 2017;7:e1073.
Ryan KM, McLoughlin DM. Peripheral blood GILZ mRNA levels in depression and following electroconvulsive therapy. Psychoneuroendocrinology . 2019;101:304–310.
Stelzhammer V, Rothermundt M, Guest PC, et al. Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy. Proteomics Clin Appl . 2011;5:644–649.
Iacob E, Tadler SC, Light KC, et al. Leukocyte gene expression in patients with medication refractory depression before and after treatment with ECT or isoflurane anesthesia: a pilot study. Depress Res Treat . 2014;2014:582380.
Lehtimaki K, Keranen T, Huuhka M, et al. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT . 2008;24:88–91.
Kranaster L, Hoyer C, Aksay SS, et al. Markers of the innate immune system in the cerebrospinal fluid in patients with severe depression. Acta Psychiatr Scand . 2017;136:140–141.
Misiaszek J, Cork RC, Hameroff SR, et al. The effect of electroconvulsive therapy on plasma beta-endorphin. Biol Psychiatry . 1984;19:451–455.
Shibasaki C, Itagaki K, Abe H, et al. Possible association between serum matrix metalloproteinase-9 (MMP-9) levels and relapse in depressed patients following electroconvulsive therapy (ECT). Int J Neuropsychopharmacol . 2018;21:236–241.
Shibasaki C, Takebayashi M, Itagaki K, et al. Altered serum levels of matrix metalloproteinase-2, -9 in response to electroconvulsive therapy for mood disorders. Int J Neuropsychopharmacol . 2016;19:1–8.
Kruse JL, Olmstead R, Hellemann G, et al. Inflammation and depression treatment response to electroconvulsive therapy: sex-specific role of interleukin-8. Brain Behav Immun . 2020;89:59–66.
Mindt S, Neumaier M, Hoyer C, et al. Cytokine-mediated cellular immune activation in electroconvulsive therapy: a CSF study in patients with treatment-resistant depression. World J Biol Psychiatry . 2020;21:139–147.
Fischler B, Bocken R, Schneider I, et al. Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci . 1992;650:326–330.
Avissar S, Nechamkin Y, Roitman G, et al. Dynamics of ECT normalization of low G protein function and immunoreactivity in mononuclear leukocytes of patients with major depression. Am J Psychiatry . 1998;155:666–671.
Kronfol Z, Nair MP, Weinberg V, et al. Acute effects of electroconvulsive therapy on lymphocyte natural killer cell activity in patients with major depression. J Affect Disord . 2002;71:211–215.
Hestad KA, Tonseth S, Stoen CD, et al. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT . 2003;19:183–188.
Fluitman SB, Heijnen CJ, Denys DA, et al. Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J Affect Disord . 2011;131:388–392.
Stelzhammer V, Guest PC, Rothermundt M, et al. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur Neuropsychopharmacol . 2013;23:1199–1207.
Rotter A, Biermann T, Stark C, et al. Changes of cytokine profiles during electroconvulsive therapy in patients with major depression. J ECT . 2013;29:162–169.
Zincir S, Ozturk P, Bilgen AE, et al. Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression. Neuropsychiatr Dis Treat . 2016;12:1389–1396.
Schwieler L, Samuelsson M, Frye MA, et al. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. J Neuroinflammation . 2016;13:1–10.
Rush G, O'Donovan A, Nagle L, et al. Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy. J Affect Disord . 2016;205:60–68.
Järventausta K, Sorri A, Kampman O, et al. Changes in interleukin-6 levels during electroconvulsive therapy may reflect the therapeutic response in major depression. Acta Psychiatr Scand . 2017;135:87–92.
Freire TFV, da Rocha NS, de Almeida Fleck MP. The association of electroconvulsive therapy to pharmacological treatment and its influence on cytokines. J Psychiatr Res . 2017;92:205–211.
Kranaster L, Hoyer C, Aksay SS, et al. Antidepressant efficacy of electroconvulsive therapy is associated with a reduction of the innate cellular immune activity in the cerebrospinal fluid in patients with depression. World J Biol Psychiatry . 2018;19:379–389.
Sorri A, Jarventausta K, Kampman O, et al. Low tumor necrosis factor-alpha levels predict symptom reduction during electroconvulsive therapy in major depressive disorder. Brain Behav . 2018;8. (no pagination):e00933.
Kruse JL, Congdon E, Olmstead R, et al. Inflammation and improvement of depression following electroconvulsive therapy in treatment-resistant depression. J Clin Psychiatry . 2018;79:17m11597.
Allen AP, Naughton M, Dowling J, et al. Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: comparison of multiple ketamine infusions and electroconvulsive therapy. J Psychiatr Res . 2018;100:24–32.
Aarsland TI, Leskauskaite I, Midttun O, et al. The effect of electroconvulsive therapy (ECT) on serum tryptophan metabolites. Brain Stimul . 2019;12:1135–1142.
Tian H, Li G, Xu G, et al. Inflammatory cytokines derived from peripheral blood contribute to the modified electroconvulsive therapy-induced cognitive deficits in major depressive disorder. Eur Arch Psychiatry Clin Neurosci . 2020.
Sahin SK, Ozyurek MB, Yasamali C, et al. Neutrophil/lymphocyte ratio in patients with major depression and the impact of electroconvulsive therapy. Ann Clin Anal Med . 2020;11(suppl 1):S57–S60.
Moschny N, Jahn K, Maier HB, et al. Electroconvulsive therapy, changes in immune cell ratios, and their association with seizure quality and clinical outcome in depressed patients. Eur Neuropsychopharmacol . 2020;36:18–28.
Belge JB, van Diermen L, Sabbe B, et al. Inflammation, hippocampal volume, and therapeutic outcome following electroconvulsive therapy in depressive patients: a pilot study. Neuropsychobiology . 2020;79:222–232.
Dahl J, Ormstad H, Aass HCD, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology . 2014;45:77–86.